doi: 10.1038/431525b.
Lung cancer: intragenic ERBB2 kinase mutations in tumours
Affiliations
- PMID: 15457249
- DOI: 10.1038/431525b
Item in Clipboard
Lung cancer: intragenic ERBB2 kinase mutations in tumours
Nature.
.
Abstract
The protein-kinase family is the most frequently mutated gene family found in human cancer and faulty kinase enzymes are being investigated as promising targets for the design of antitumour therapies. We have sequenced the gene encoding the transmembrane protein tyrosine kinase ERBB2 (also known as HER2 or Neu) from 120 primary lung tumours and identified 4% that have mutations within the kinase domain; in the adenocarcinoma subtype of lung cancer, 10% of cases had mutations. ERBB2 inhibitors, which have so far proved to be ineffective in treating lung cancer, should now be clinically re-evaluated in the specific subset of patients with lung cancer whose tumours carry ERBB2 mutations.
Similar articles
-
ERBB2 kinase domain mutation in the lung squamous cell carcinoma.Cancer Lett. 2006 Jun 8;237(1):89-94. doi: 10.1016/j.canlet.2005.05.026. Epub 2005 Jul 18. Cancer Lett. 2006. PMID: 16029927
-
Non-small-cell lung cancer and Ba/F3 transformed cells harboring the ERBB2 G776insV_G/C mutation are sensitive to the dual-specific epidermal growth factor receptor and ERBB2 inhibitor HKI-272.Cancer Res. 2006 Jul 1;66(13):6487-91. doi: 10.1158/0008-5472.CAN-06-0971. Cancer Res. 2006. PMID: 16818618
-
EGFR, ERBB2, and KRAS mutations in Korean non-small cell lung cancer patients.Cancer Genet Cytogenet. 2007 Mar;173(2):107-13. doi: 10.1016/j.cancergencyto.2006.10.007. Cancer Genet Cytogenet. 2007. PMID: 17321325
-
Epidermal growth factor receptor activation: how exon 19 and 21 mutations changed our understanding of the pathway.Clin Cancer Res. 2006 Dec 15;12(24):7222-31. doi: 10.1158/1078-0432.CCR-06-0627. Clin Cancer Res. 2006. PMID: 17189393 Review.
-
Epidermal growth factor receptor mutations, small-molecule kinase inhibitors, and non-small-cell lung cancer: current knowledge and future directions.J Clin Oncol. 2005 Apr 10;23(11):2556-68. doi: 10.1200/JCO.2005.07.799. Epub 2005 Mar 14. J Clin Oncol. 2005. PMID: 15767641 Review.
Cited by
-
Acquired differential regulation of caspase-8 in cisplatin-resistant non-small-cell lung cancer.Cell Death Dis. 2012 Dec 20;3(12):e449. doi: 10.1038/cddis.2012.186. Cell Death Dis. 2012. PMID: 23254292 Free PMC article.
-
Accurate calculation of mutational effects on the thermodynamics of inhibitor binding to p38α MAP kinase: a combined computational and experimental study.J Chem Theory Comput. 2013 Jul 9;9(7):3151-3164. doi: 10.1021/ct400104x. J Chem Theory Comput. 2013. PMID: 23914145 Free PMC article.
-
Genetic and biochemical alterations in non-small cell lung cancer.Biochem Res Int. 2012;2012:940405. doi: 10.1155/2012/940405. Epub 2012 Aug 15. Biochem Res Int. 2012. PMID: 22928112 Free PMC article.
-
Mutation analysis of 24 known cancer genes in the NCI-60 cell line set.Mol Cancer Ther. 2006 Nov;5(11):2606-12. doi: 10.1158/1535-7163.MCT-06-0433. Epub 2006 Nov 6. Mol Cancer Ther. 2006. PMID: 17088437 Free PMC article.
-
A Comparative and Comprehensive Review of Antibody Applications in the Treatment of Lung Disease.Life (Basel). 2022 Jan 17;12(1):130. doi: 10.3390/life12010130. Life (Basel). 2022. PMID: 35054524 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases
Research Materials
Miscellaneous
